Advik Laboratories reported a net loss of Rs 23.8 lakh for the June 2026 quarter. The company faces BSE trading suspension due to unpaid listing fees and significant audit qualifications on investments and stalled capital work-in-progress.
Advik Laboratories Posts Rs 23.8 Lakh Loss, Faces BSE Trading Suspension
Advik Laboratories reported a net loss of Rs 23.80 lakh for the quarter ended June 30, 2026, a slight increase from Rs 22.01 lakh in the same period last year. Revenue from operations remained nil. ## What just happened The company's statutory auditor issued a qualified conclusion for the standalone financial results. Key concerns include investments valued at Rs 53.80 lakh at acquisition cost without fair value determination, with share certificates unavailable for verification. Additionally, Rs 2.12 crore in capital work-in-progress (CWIP) is stalled, requiring technical evaluation for potential impairment. ## Why this matters The qualified audit report raises serious questions about the accuracy of the company's financial statements, particularly concerning its assets. Furthermore, Advik Laboratories has not paid BSE listing fees since FY21-22, leading to trading suspension and restrictions to a Trade-for-Trade basis on the first trading day of each week. ## The backstory Advik Laboratories has been facing operational challenges, evidenced by nil revenue for the quarter. The non-payment of BSE listing fees has persisted for several years, resulting in the current trading limitations. The company is also awaiting renewal of its drug manufacturing licenses from the FDA. ## What changes now Trading in Advik Laboratories' shares is restricted. Investors face uncertainty due to the audit qualifications and the pending renewal of manufacturing licenses. The company needs to clear its dues to the BSE to normalize trading and address the auditor's concerns regarding investments and CWIP. ## Risks to watch Persistent nil revenue, significant audit qualifications on assets, and continued BSE trading restrictions are major risks. Failure to renew drug manufacturing licenses would further jeopardize future operations. ## Peer comparison (No reliable peer comparison data available from the filing.) ## Context metrics (time-bound) * **Net Loss:** Rs. 23.80 lakh (Jun-26 Quarter) * **Net Loss:** Rs. 22.01 lakh (Jun-25 Quarter) * **Stalled CWIP:** Rs. 2.12 crore * **Investment Valuation Issue:** Rs. 53.80 lakh * **BSE Listing Fees Due:** Since FY 2021-22 ## What to track next Investors should monitor the renewal status of the FDA drug manufacturing licenses and the company's progress in settling outstanding BSE listing fees to restore full trading. Any progress on addressing the auditor's qualifications regarding investments and CWIP will also be crucial.
